KH176 Phase 1 Clinical trials

December 4, 2015 – FOR IMMEDIATE RELEASE Khondrion reports successful outcome of KH176 Phase 1 Clinical trials NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today the...

Khondrion partner in SysMedPD EU research project

Press Release New EU research project SysMedPD joins forces between universities’ research facilities and Khondrion New EU research initiative aims to develop drugs to slow down the progression of Parkinson’s disease Nijmegen, 01 December 2015 – Parkinson’s disease...

EMA Orphan Drug Designation

EMA Orphan Drug Designation Khondrion has received an Orphan Drug Designation from the European Commission of its frontrunner compound KH176, in the treatment of Leigh syndrome (EU/3/14/1336) Find more articles BIO-Europe 2018: Interview with Mike Ward, Chief Content...

Interview PharmaBoardroom

Read the interview on pharmaboardroom.com Interview: Jan Smeitink – CEO, Khondrion, The Netherlands Jan Smeitink, CEO of Khondrion, a young biotech company designing highly innovative solutions for people suffering from mitochondrial diseases, provides an overview of...

Khondrion welcomes Hans Schikan

Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that Hans Schikan, former CEO of...

EMA Orphan Drug Designation for MELAS syndrome

Khondrion receives Orphan Drug Designation for treatment of MELAS syndrome NIJMEGEN – Khondrion, the Dutch pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that the European Commission has granted Khondrion...